News

News-Medical.Net on MSN2h
Existing therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy
A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...
Existing treatments may help fight symptoms of severe form of muscular dystrophy
A new study led by researchers at the Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...
Pharmaceutical Technology on MSN5d
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).
pharmaphorum2d
Italfarmaco closes on EU okay for Duchenne drug
Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...
Managed Healthcare Executive13d
MRI Imaging May Be Important Biomarker in DMD
A trial found magnetic resonance imaging correlated with physical function tests in patients with Duchenne muscular dystrophy ...
Pharmabiz2d
EMA grants conditional marketing authorization to Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy
EMA grants conditional marketing authorization to Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy: Amsterdam, The Netherlands Monday, April 28, 2025, 16:00 Hrs [IST] ...
TMCnet6d
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
It is designed to enable targeted muscle tissue delivery and promote exon skipping in the nucleus ... by the U.S. Food and Drug Administration for the treatment of DMD mutations amenable to exon 51 ...